At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
entinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating entinostat and pembrolizumab for Non-Small Cell Lung Cancer and 2 related conditions. Completed, enrolled 191 participants across 11 sites.
Detailed Summary
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in participants with NSCLC, Melanoma, and Mismatch-Repair Proficient CRC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartAug 2015
Primary CompletionSep 2022
TodayJul 2026
First PostedMay 7, 2015
Enrollment StartAug 26, 2015
Primary CompletionSep 29, 2022
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 11.2 years ago
Interventions
entinostatdrug
An orally available histone deacetylases inhibitor (HDACs)
pembrolizumabdrug
A selective humanized monoclonal antibody (mAb)